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Abstract
Background: Recent studies have suggested that passive or active immunization with anti-amyloid
β peptide (Aβ) antibodies may enhance microglial clearance of Aβ deposits from the brain.
However, in a human clinical trial, several patients developed secondary inflammatory responses in
brain that were sufficient to halt the study.
Methods: We have used an in vitro culture system to model the responses of microglia, derived
from rapid autopsies of Alzheimer's disease patients, to Aβ deposits.
Results: Opsonization of the deposits with anti-Aβ IgG 6E10 enhanced microglial chemotaxis to
and phagocytosis of Aβ, as well as exacerbated microglial secretion of the pro-inflammatory
cytokines TNF-α and IL-6. Indomethacin, a common nonsteroidal anti-inflammatory drug (NSAID),
had no effect on microglial chemotaxis or phagocytosis, but did significantly inhibit the enhanced
production of IL-6 after Aβ opsonization.
Conclusion: These results are consistent with well known, differential NSAID actions on immune
cell functions, and suggest that concurrent NSAID administration might serve as a useful adjunct to
Aβ immunization, permitting unfettered clearance of Aβ while dampening secondary, inflammation-
related adverse events.
Background
Chemotactic and phagocytic responses of microglia to
amyloid β peptide (Aβ) have been inferred from postmor-
tem autopsy evaluations [1-3], animal studies [4,5], and
an in vitro model in which cultured rodent microglia were
placed directly on Alzheimer's disease (AD) cortical sec-
tions [5,6]. Although these valuable experiments confirm
that microglia cluster around and may help clear Aβ
deposits, new questions have arisen concerning the effects
of various agents on these microglial interactions with Aβ.
In particular, several studies have indicated that the
opsonization of Aβ deposits with anti-Aβ antibodies facil-
itates microglia-mediated Aβ clearance [6,7]. Here, bind-
ing of the antibodies to the Aβ target presumably
enhances microglial recognition of and subsequent
responses to the target through Fc receptors expressed by
the microglia [6,7]. Based on these results, it has been sug-
gested that microglial responses to Aβ might represent so
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beneficial an inflammatory action that anti-inflammatory
drugs might actually be detrimental as a treatment for AD
[8]. Alternatively, multiple epidemiologic studies [9,10]
have reported decreased risk for AD in persons who take
common nonsteroidal anti-inflammatory drugs
(NSAIDs).
Over the last decade, our laboratory has developed relia-
ble methods for culturing microglia from rapid (< 4 hour)
brain autopsies of AD patients [11,12]. These cultures
uniquely match the species, developmental stage, and dis-
ease state of AD subjects, and provide the ready experi-
mental manipulability that is helpful in assessing
complex physiologic processes such as chemotaxis,
phagocytosis, secretory activity, and drug responses. In
order to quantitatively assay these processes in the context
of microglial interactions with Aβ, we seeded AD micro-
glial cultures into wells containing pre-aggregated Aβ1-42
spots dried down to the well floor. Subsequent experi-
ments measured migration of the cells to the Aβ spots,
phagocytosis of the Aβ spots, pro-inflammatory cytokine
secretion, and the effects on these processes when Aβ
spots were opsonized with an anti-Aβ antibody or when
microglia were treated with a common nonsteroidal anti-
inflammatory drug (NSAID), indomethacin. Overall,
opsonization with Aβ antibody enhanced microglial
migration to and phagocytosis of Aβ. Indomethacin had
little to no effect on these responses, but did significantly
inhibit microglial secretion of IL-6.
Methods
AD microglia cultures
Cultures of microglia from rapid (< 4 hours) autopsies of
six antemortem-evaluated, neuropathologically-con-
firmed AD patients were prepared using our previously
published methods [11,12]. By immunoreactivity, these
cultures are consistently negative for neuron, astrocyte,
oligodendrocyte, and fibroblast markers, consistently
positive for multiple markers of activated microglia, and
readily maintained at purities of 98% or higher [11,12].
Microglia cultures from all six AD patients were used for
biochemical assays. Additional cultures from one of these
patients were used for quantitative evaluation of chemo-
taxis and phagocytosis, and additional cultures from two
more of these patients were used for qualitative replica-
tion of the chemotaxis and phagocytosis results. At 3–7
days post-plating, the microglia were trypsinized and
replated at 50,000 cells/well in 12-well plates. Prior to
replating, 2 µl of a 1 mM solution of Aβ1-42 (Bachem) in
PBS (pH 7.4) was dried down to the well floor. Each well
received two such Aβ spots, and there were three wells per
experimental condition, so that a total of six Aβ spots were
quantified per experimental condition. Serum-free
medium was used throughout the experiments. Control
wells containing no Aβ or no microglia were also
prepared.
Treatment with anti-Aβ antibody
Prior to seeding with microglia, selected wells were pre-
treated with vehicle (medium) only or with 10 µg/ml
6E10 (Signet Laboratories), a mouse monoclonal anti-
body directed against the first 17 (N-terminal) amino
acids in the Aβ sequence. In some experiments, a 2 µg/ml
concentration of 6E10 was included in order to evaluate
effects at a lower dose.
Treatment with indomethacin
Prior to seeding with microglia, selected wells were pre-
treated with vehicle (medium) only or with 1.0 µg/ml
indomethacin. Indomethacin, at 1.0 µg/ml, and vehicle
were also replenished at Days 3, 6, and 9 in the course of
medium changes. The 1.0 µg/ml indomethacin concentra-
tion is at the upper end of the physiologically normal
range achieved in blood after therapeutic doses of the
drug [13], and was chosen to insure that any failure of
indomethacin to affect chemotaxis to or phagocytosis of
Aβ was not due to inadequate drug dosage. In some exper-
iments, a 0.1 µg/ml concentration of indomethacin,
which is at the lower end of the physiologically normal
range achieved in blood after therapeutic doses, was
included in order to evaluate effects at a lesser
concentration.
Cytochemistry and immunocytochemistry
For qualitative evaluations of microglial responses to Aβ,
microglial cultures were briefly fixed with 4% buffered
paraformaldehyde, then immunoreacted overnight with
1:1000 (0.5 µg/ml) LN3 antibody (MP Biomedical)
directed against the major histocompatibility complex
type II cell surface glycoprotein, using our previously pub-
lished methods [11,14,15]. Vectastain ABC kits (Vector
Laboratories) were employed using the manufacturer's
protocols to detect immunoreactivity with bright field
optics. Aβ spots could be sufficiently resolved under these
conditions by their modest opaqueness under bright field
optics. To visualize Aβ spots in phagocytosis experiments,
the wells were washed gently in distilled water (3 × for 5
min each), incubated with 0.1% Thioflavine S (Sigma) for
10 min, washed once in distilled water (5 min), then
dehydrated and fixed with 4% buffered paraformalde-
hyde. In additional experiments, Aβ immunocytochemis-
try was applied in selected wells so as to graphically
illustrate Aβ removal and microglial uptake of Aβ. In these
studies, microglial cultures with Aβ spots were briefly
fixed with 4% buffered paraformaldehyde and incubated
overnight with 1:1000 (1 µg/ml) anti-Aβ antibody 4G8
(Signet Laboratories). Detection of immunoreactivity was
accomplished using Vectastain ABC kits (Vector Laborato-
ries) and the manufacturer's suggested protocols.Journal of Neuroinflammation 2005, 2:18 http://www.jneuroinflammation.com/content/2/1/18
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Microglial migration to Aβ spots
Microglial cultures were assessed on Day 3 and Day 9 after
initial plating. Each Aβ spot was visualized under phase
contrast optics at 100 × (10 × objective), and photomon-
tages were made of the spot and surrounding area out to
a radius of 2 mm from the spot perimeter. A grid was then
placed over the photomontages. The number and percent-
ages of microglia within four 500 µm × 500 µm (0.25
mm2) grid squares centered on the Aβ spot and within sets
of four 500 µm × 500 µm squares at progressively greater
distances from the spot were recorded. The distance inter-
vals for the grid squares were 0, 500, 1000, 1500, and
2000 µm from the Aβ spot, and each distance interval was
measured in quadruplicate (Fig. 1). A total of 141,455
microglia were individually hand-counted in this way.
Chemotaxis was evaluated by changes in the distributions
of microglia relative to the Aβ spots over time, with rela-
tively flat distributions indicative of little or no chemo-
taxis, and increasingly negative slopes to the distributions
indicative of migration toward the Aβ spots (Fig. 1).
Slopes of the distributions (m) were operationally defined
as the "chemotactic index" [15] for each condition, and
the statistical reliability of the measures was assessed with
Pearson's Product Momentum (R) statistic and with anal-
ysis of variance (ANOVA) techniques. The simplest ANO-
VAs assessed, for each treatment condition, significant
differences in the distributions of microglia over the pro-
gressive distance intervals from the Aβ spot, with percent-
age of microglia at a particular distance (grid square) as
the dependent variable and distance from the Aβ spot (0,
500, 1000, 1500, and 2000 µm) as the single factor. Pear-
son's R Statistic was then run to confirm that the altera-
tions in microglial distributions were consistent with
chemotaxis (i.e., showed a significant negative correlation
with distance from Aβ) rather than some other response
pattern. Dose dependence was evaluated using two-way
ANOVAs, with percentage of microglia as the dependent
variable, distance from the Aβ spot as the first factor, and
drug dose as the second factor. Significant interactions of
distance with drug dose thereby provided statistical evi-
dence that the different drug doses differentially affected
microglial distributions. A similar approach was taken for
comparisons of different treatment conditions (e.g., anti-
Aβ antibody exposure ± indomethacin treatment). All
data collection was by a technician blind to experimental
condition.
Tests of microglial proliferation
BrdU staining kits (Zymed/Invitrogen) were applied to
selected wells in order to assess whether shifts in micro-
glial distributions over time might be due to differential
proliferation of microglia relative to Aβ spots as opposed
to migration of the cells. Staining with BrdU followed the
manufacturer's recommended directions.
Microglial phagocytosis of Aβ spots
At Day 12 postplating, selected wells were histochemically
reacted with Thioflavine S, as described earlier, and visu-
alized at 100 × (10 × objective) with a confocal micro-
scope. Using the ability of the confocal microscope to
optically section an object at precise distances, the
number of 10 µm optical slices from the well floor to the
top of the remaining Aβ spot was recorded by an investi-
gator blinded to the experimental conditions imposed in
each well. The data were then assessed statistically using 2-
way ANOVAs, with spot thickness as the outcome meas-
ure, antibody treatment (vehicle only, 2 µg/ml anti-A↕
IgG, or 10 µg/ml anti-A↕  IgG) as the first factor, and
NSAID treatment (vehicle only, 0.1 µg/ml indomethacin,
or 1.0 µg/ml indomethacin) as the second factor.
Microglial secretion of cytokines
To assess the effects of opsonization with anti-Aβ antibod-
ies, microglial cultures were preincubated with vehicle or
10 µg/ml anti-Aβ monoclonal 6E10 followed by 4 hours
exposure to 0 or 10 µM preaggregated Aβ1-42 (Bachem).
Conditioned medium was then subjected to TNF-α ELISA
(R&D Systems) using the manufacturer's protocols. To
confirm the results with another pro-inflammatory
cytokine, and to evaluate the interaction of indomethacin
with antibody opsonization, microglial cultures were pre-
incubated with vehicle or 10 µg/ml 6E10, as before, but in
the presence or absence of 1 µg/ml indomethacin. After
incubation for 4 hours with 0 or 10 µM Aβ1-42, the con-
ditioned medium was subjected to IL-6 ELISA (R&D Sys-
tems) using the manufacturer's protocols.
Results
Microglial migration to Aβ spots
Overall and within each treatment condition there were
shifts in microglial distributions, consistent with chemo-
taxis, that were both visually apparent (Figs. 2A, 2C) and
statistically significant (Figs. 2B, 2D). By Day 3, the great-
est concentrations of microglia were midway between the
most distal and proximal points from the Aβ spots (FDis-
tance = 40.1, P = 0.000; R = -.17, P = 0.000; m = -.016) (Fig.
2B). By Day 9, the greatest concentrations of microglia
were at or adjacent to the spots (FDistance = 99.2, P = 0.000;
R = -.41, P = 0.000; m = -.041) (Fig. 2D). Microglia seeded
into wells without Aβ spots essentially remained ran-
domly distributed throughout these time periods.
Opsonization with anti-Aβ antibodies significantly
enhanced chemotaxis-like shifts in microglial distribu-
tions, an effect that was especially prominent at Day 9
(Table 1) (Fig. 3). Indomethacin had no significant or
obvious effect on changes in microglial distributions over
time under any of the Aβ antibody treatment conditions.
Indeed, the largest chemotactic index (slope) observed in
the study occurred at the highest dose of indomethacin
(1.0 µg/ml indomethacin plus 10 µg/ml anti-Aβ) (FDistanceJournal of Neuroinflammation 2005, 2:18 http://www.jneuroinflammation.com/content/2/1/18
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= 38.9, P = 0.000; R = 0.69, P = 0.000; m = -.073), and the
second largest chemotactic index occurred at the second
highest dose of indomethacin (0.1 µg/ml indomethacin
plus 10 µg/ml anti-Aβ) (FDistance = 12.9, P = 0.000; R = -.53,
P = 0.000; m = -.060 (Fig. 3).
Differential proliferation versus chemotaxis
Proliferation of microglia more proximal to the Aβ spots,
rather than true chemotaxis, did not explain the shifts in
microglial distributions that were exhibited over time
under the various treatment conditions. There was little to
no BrdU staining under any condition (not shown) and,
in fact, there was a slight but significant decrease in micro-
glial numbers in all treatment conditions and overall from
Day 3 (mean microglial density/0.25 mm2 grid square =
40.8 ± 0.3) to Day 9 (mean microglial density/0.25 mm2
grid square = 37.8 ± 0.4) (FOverall = 34.5, P = 0.000). Con-
sistent with our previous experience, AD microglia stimu-
lated with M-CSF as a positive control showed little to no
evidence of proliferation. However, M-CSF-stimulated
THP-1 cells (a monocyte line often used as a surrogate for
microglia) that were run in parallel did show clear
Paradigm for estimation of microglial chemotaxis to Aβ Figure 1
Paradigm for estimation of microglial chemotaxis to Aβ. Upper left panel shows a hypothetical example at Day 1, 
when microglia (black dots) are uniformly distributed relative to Aβ spots (gray circle). A plot of microglial density within 500 
µm × 500 µm grid squares at increasing proximity to the spot (lower left) is therefore relatively flat, with a slope near 0, indic-
ative of little or no migratory activity at this early time point. After 9 days (right panels), microglia are clustered over and 
around the Aβ spot, yielding a pronounced slope to the plot, consistent with chemotaxis to the Aβ. Previous studies have 
referred to such slopes as "chemotactic indices" [c.f., 15].
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Typical responses of cultured AD microglia to pre-aggregated Aβ1-42 spots dried down to the well floor Figure 2
Typical responses of cultured AD microglia to pre-aggregated Aβ1-42 spots dried down to the well floor. A) 
Micrograph of Aβ spot (light brown stain) and LN3 immunoreactive microglia (blue stain) 3 days postplating (vehicle control) 
(4 × objective). B) Graphic summary of microglial distributions at 3 days postplating (pooled data over all conditions). C) Paral-
lel well 9 days postplating (vehicle control) (4 × objective). Wells seeded with microglia but without Aβ spots exhibited only 
random distributions of cells (not shown). D) Graphic summary of microglial distributions at Day 9 (pooled data over all con-
ditions). Similar and highly significant shifts over time were observed in all treatment conditions when Aβ spots were present 
(see text).
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proliferation under the same BrdU assay conditions (data
not shown).
Microglial phagocytosis of Aβ
After incubation with microglia under the various experi-
mental conditions, visible degradation of Aβ spots was
apparent (Fig. 4A), whereas Aβ spots in wells not
containing microglia remained visibly intact over the
same time periods (Fig. 4B). Concurrent with degradation
of the Aβ spots, microglia in contact with the spots
became Aβ immunoreactive (Fig. 4A), whereas they
exhibited little to no Aβ immunoreactivity prior to their
being seeded into the wells (Fig. 4C). Opsonization of Aβ
spots with 2 µg/ml anti-Aβ antibody 6E10 (F = 28.7, P =
0.006) or 10 µg/ml anti-Aβ antibody 6E10 (F = 35.3, P =
0.004) resulted in significantly smaller (thinner) Aβ spots
compared to the vehicle control condition (Fig. 4D).
These effects were not significantly or materially inhibited
by indomethacin even at the highest, 1.0 µg/ml
indomethacin concentration (for 2 µg/ml anti-Aβ ± 1.0
µg/ml indomethacin: F = 0.3, P = 0.639) (for 10 µg/ml
anti-Aβ plus ± 1.0 µg/ml indomethacin: F = 0.9, P = 0.402)
(Fig. 4D).
Microglial secretion of cytokines
Consistent with our previous studies covering a wide
range of cytokines, chemokines, and inflammatory toxins
[12], exposure of microglia to Aβ significantly enhanced
secretion of TNF-α (Fig. 5A) and IL-6 (Fig. 5B) compared
to cultures that were not exposed to Aβ. Opsonization
with 10 µg/ml anti-Aβ antibody 6E10 significantly
enhanced Aβ-induced TNF-α (Fig. 5A) and IL-6 secretion
(Fig. 5B). Enhancement of IL-6 expression, however, was
significantly decreased by indomethacin treatment (Fig.
5B). Cytokine secretion is typically a fairly rapid response
that wanes over time. Presumably, cytokine receptive cells
then undergo more long-lasting responses such as
enhanced chemotactic or phagocytic behaviors. Consist-
ent with this, we observed significant changes in TNF-α
and IL-6 levels 4 hours after exposure of microglia to Aβ,
but not 3, 6, or 9 days after exposure to Aβ (data not
shown).
Discussion
The present study found that AD microglia in vitro
migrate toward Aβ aggregates, attempt to phagocytose the
aggregates, and increase their secretion of TNF-α and IL-6
in the process. Opsonization of Aβ aggregates with anti-
Aβ antibody 6E10 significantly enhanced these processes.
By contrast, the common NSAID indomethacin had no
material or statistical effect on microglial migration or
phagocytosis, but significantly inhibited the increased IL-
6 secretion observed with anti-Aβ opsonization.
The shifts in microglial distributions relative to Aβ spots
over time are most parsimoniously explained by chemo-
tactic responses to Aβ. Proliferation of microglia more
proximal to Aβ aggregates was not observed and, in fact,
BrdU reactivity, a common marker for cell proliferation,
was negligible at all distances from the aggregates. Chem-
okinesis, enhanced but undirected movement of cells,
also did not appear to explain the results, since microglial
migration exhibited the gradient characteristics of chemo-
taxis, with progressive increases in the density of microglia
at distances more proximal to Aβ aggregates. In addition,
microglia are now well established to express receptors
that can mediate chemotactic behaviors and that appear
to have Aβ as a ligand. These include the macrophage
scavenger receptor [16-18], the receptor for advanced gly-
cation endproducts (RAGE) [15], the formyl peptide
receptor [19], and others [20,21]. RAGE, in particular, has
been shown to help mediate microglial migration to Aβ
spots in an in vitro paradigm similar to that used here, and
this migration could be inhibited by anti-RAGE Fab frag-
ments [15].
AD microglia in vitro also exhibited behaviors consistent
with phagocytosis of Aβ aggregates. Entering the para-
digm, the microglia showed little or no Aβ immunoreac-
tivity. After 12 days incubation with Aβ spots, the
microglia were highly immunoreactive for Aβ and the
spots decreased in size. Aβ spots without microglia
remained essentially intact over the same time period.
Previous ultrastructural and other studies [3,22,23] have
also identified Aβ filaments within microglia in the vicin-
ity of Aβ deposits in AD cortex. Although it remains pos-
sible that the intracellular Aβ within microglia in the AD
brain may have been produced by the cells [24] rather
than phagocytosed from an extracellular deposit, this is
clearly not the process observed in the present in vitro
studies. We conclude, therefore, that AD microglia in vitro
do phagocytose aggregated Aβ deposits. Given the
Table 1: Effects of opsonization with anti-Aβ antibody 6E10 on 
chemotaxis-like changes in microglia distributions
ANOVA PEARSON'S SLOPE
FP R P m
Day 3
0 µg/ml anti-Aβ 3.7 0.007 -0.26 0.005 -0.022
2 µg/ml anti-Aβ 2.5 0.040 -0.14 NS -0.023
10 µg/ml anti-Aβ 5.5 0.000 -0.27 0.003 -0.027
Dose dependence* 3.6 0.008
Day 9
0 µg/ml anti-Aβ 5.6 0.000 -0.37 0.000 -0.040
2 µg/ml anti-Aβ 11.2 0.000 -0.050 0.000 -0.051
10 µg/ml anti-Aβ 16.4 0.000 -0.57 0.000 -0.056
Dose dependence* 2.3 0.050
*Dose × distance interaction termJournal of Neuroinflammation 2005, 2:18 http://www.jneuroinflammation.com/content/2/1/18
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Microglial distributions after 9 days incubation with Aβ spots Figure 3
Microglial distributions after 9 days incubation with Aβ spots. A) Treatment with 2 µg/ml anti-Aβ antibody plus (yel-
low) or minus (green) 1 µg/ml indomethacin (INDO). B) Treatment with vehicle control (red) or 10 µg/ml anti-Aβ antibody 
plus (yellow) or minus (green) 1 µg/ml indomethacin. C) Representative phase contrast image (4 × objective) of microglia and 
an Aβ spot when treated with vehicle only. D) Representative phase contrast image (4 × objective) of microglia and an Aβ spot 
when treated with 10 µg/ml anti-Aβ antibody plus 1 µg/ml indomethacin.
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Evidence for phagocytosis of Aβ by AD microglia in vitro under the various experimental conditions Figure 4
Evidence for phagocytosis of Aβ by AD microglia in vitro under the various experimental conditions. A) Twelve 
days after plating AD microglia with Aβ spots, diminution of the spots was visually apparent and microglia concurrently had 
become immunoreactive for Aβ even under vehicle control conditions, as shown here (anti-Aβ antibody 4G8 immunocyto-
chemistry). B) In the absence of microglia, the Aβ spots remained visibly intact (phase contrast). C) Likewise, prior to exposure 
to Aβ spots the microglia exhibited little or no immunoreactivity for Aβ (anti-Aβ antibody 4G8 immunocytochemistry). D) 
Summary data illustrating the effects of indomethacin and 6E10 opsonization on Aβ spot thickness. Microglia in this model sys-
tem carpet the top of Aβ spots (c.f., Fig. 2C) and therefore appear to clear the Aβ from the top down, resulting in progressive 
thinning of the spot, as measured here. With prolonged exposure, cracks and holes in the spot appear, as shown in Fig. 4A.
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experimental accessibility of the model, it will be of inter-
est in future to evaluate the molecular fate of phagocy-
tosed Aβ in cultured AD microglia.
Exposure to aggregated Aβ also induced significant
increases in TNF-α and IL-6 secretion, confirming our pre-
vious experiments [12] and those of others [25-27] with
TNF-α, IL-6, and a broad range of chemokines, cytokines,
and inflammatory toxins such as reactive oxygen/nitrogen
species. Pathways for enhancing TNF-α and IL-6 secretion
have been demonstrated, including NF-kB and C/EBP
transcriptional mechanisms, both of which are enhanced
in pathologically-vulnerable regions of the AD brain
[28,29].
Opsonization of Aβ spots with anti-Aβ antibody 6E10 sig-
nificantly enhanced microglial migration to the spots,
phagocytosis of the spots, and cytokine secretion. Similar
effects of opsonization on microglial migration and
phagocytosis have also been reported using anti-Aβ anti-
bodies and an in vitro preparation in which cultured
rodent microglia were seeded onto postmortem AD cortex
sections laden with Aβ deposits [6]. Soluble Fab fragments
containing the Fc region ligand for Fc receptor binding
inhibited Aβ removal in this paradigm. These effects are
consistent with the classic mechanisms of antibody
opsonization of immune targets by antibodies specific to
epitopes on the target. Scavenger cells that express
receptors to the Fc region of the antibodies are then
directed to or become focused at the site where the
antibody-bound target resides. Fc receptor activation, in
addition, activates scavenger cells, promoting attack and
phagocytosis. Recently, scientists at Elan Pharmaceuticals
have attempted to harness these mechanisms to enhance
Aβ clearance, using immunization with Aβ to drive pro-
duction of anti-Aβ antibodies for subsequent Aβ opsoni-
zation [6,30]. Although there is controversy about the
exact site of action of the antibodies (e.g., brain versus
peripheral circulation) [6,30,31], this approach does
clearly result in significant and sometimes dramatic reduc-
tions of Aβ burden in transgenic mouse models [6], as
well as the in vitro model tested here, and may also have
been effective in human patients receiving Aβ immuniza-
tion [30].
Unfortunately, however, inflammatory responses are
often a two-edged sword. Fc receptor binding is known to
enhance the activation and pro-inflammatory secretory
responses of scavenger cells that bear Fc receptors, and
microglia do express these receptors [6,32]. The increased
TNF-α and IL-6 secretion observed in the present experi-
ments after opsonization of Aβ aggregates with a specific
anti-Aβ antibody, 6E10, is therefore not unexpected. On
activation, microglial cells are, in fact, well established to
secrete a wide range of inflammatory mediators that could
not only cause damage to neurons and neurites locally,
but also, if sufficiently activated, provide signalling to
peripheral immune cells to provoke a more generalized
and severe response such as that reported in several Aβ-
immunized patients who experienced lethal adverse reac-
tions [30].
The vast majority of NSAIDs in use today are based on the
principle of cyclooxygenase inhibition, and cyclooxygen-
ase inhibition, in turn, is well established to downregulate
a wide range of acute phase reactants. Interestingly, how-
ever, mechanisms for chemotaxis to and phagocytosis of
Effects on microglial TNF-α (A) and IL-6 (B) secretion into  the medium in the presence or absence of Aβ, as well as  after pretreatment of Aβ with 10 µg/ml anti-Aβ antibody  6E10 Figure 5
Effects on microglial TNF-α (A) and IL-6 (B) secre-
tion into the medium in the presence or absence of 
Aβ, as well as after pretreatment of Aβ with 10 µg/ml 
anti-Aβ antibody 6E10. Opsonization with 6E10 signifi-
cantly enhanced (P < 0.05) (*) TNF-α and IL-6 levels com-
pared to Aβ alone. IL-6 experiments also measured the effect 
of 1 µg/ml indomethacin on 6E10 exacerbation of cytokine 
secretion. Indomethacin significantly reduced this effect (P < 
0.05) (#).Journal of Neuroinflammation 2005, 2:18 http://www.jneuroinflammation.com/content/2/1/18
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an inflammatory target are not necessarily cyclooxygenase
dependent. In a survey, for example, of the first 100 pub-
lications retrieved from PubMed using the search phrase
"indomethacin AND chemotaxis", the majority of studies
found no effect of indomethacin on chemotaxis, and
some of the papers actually reported enhanced chemo-
taxis after indomethacin exposure. Such findings have
been suggested to explain why physicians commonly pre-
scribe NSAIDs to control fever and other secondary
inflammatory responses without being unduly concerned
about hampering immune-mediated removal of the fever-
inducing agent. Similarly, in the present experiments
indomethacin had no material or statistically significant
effect on microglial chemotaxis to or phagocytosis of Aβ
aggregates, but did significantly inhibit the exacerbated IL-
6 response under opsonized conditions. Although it is
never certain that in vitro results will fully apply to the in
vivo state, these results suggest that indomethacin or an
NSAID like it might be a useful adjunct to Aβ immuniza-
tion strategies.
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